Dataset Information

Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in the later stages of CKD

ABSTRACT: The interplay of gut microbiota with the kidney system, characteristic to reduced kidney function and increased concentrations of urea in gut; in turn increases bacterial urease activity and generation of uremic toxins. Knowledge on these underlying bidirectional molecular mechanisms is nevertheless still limited. In this exploratory study, fecal proteomics analysis was performed, to investigate this largely unexplored biological material as a source of relevant information reflecting the gut-kidney axis at protein level. Specifically, fecal suspension samples from patients with chronic kidney disease (CKD); CKD1 (n = 12) and CKD4 (n = 17) were analysed by high resolution LC-MS/MS. Protein identification was performed using both the human and bacterial UniProt RefSeq reviewed databases, identifying 701 and 1011 unique proteins, respectively. Differential expression analysis (CKD4/CKD1) revealed significance for human proteins previously associated with reduced saccharolytic fermentation, inflammation and CKD, including pancreatic alpha-amylase and galectin-3-binding protein. Significant changes in bacterial proteins such as glyceraldehyde-3-phosphate dehydrogenase, suggest differential butyrate synthesis in CKD4/CKD1. Quantitatively measured decrease of pancreatic alpha-amylase and butyrate in CKD4/CKD1, supported these hypotheses. In conclusion, this analysis highlighted the presence of inflammation and suggested reduced saccharolytic fermentation affecting butyrate synthesis pathways in later disease stages. Validation by a multi-omics analysis is planned.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Sonnal Lohia

LAB HEAD: Dr Antonia Vlahou

PROVIDER: PXD048778 | Pride | 2025-06-02

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	221215L000007_fecal_9.mgf	Mgf
	221215L000007_fecal_9.raw	Raw
	221215L000007_fecal_9_bacteria.msf	Msf
	221215L000007_fecal_9_bacteria.mzid.gz	Mzid
	221215L000007_fecal_9_human.msf	Msf

Items per page:

1 - 5 of 181

Publications

Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in CKD.

Lohia Sonnal S Valkenburg Sophie S Stroggilos Rafael R Lygirou Vasiliki V Makridakis Manousos M Zoidakis Jerome J Verbeke Francis F Glorieux Griet G Vlahou Antonia A

Heliyon 20240611 12

<h4>Objective</h4>The interplay of gut microbiota with the kidney system in chronic kidney disease (CKD), is characterized by increased concentrations of uric acid in the gut, which in turn, may increase bacterial uricase activity and may lead to the generation of uremic toxins. Nevertheless, knowledge on these underlying bidirectional molecular mechanisms is still limited.<h4>Methods</h4>In this exploratory study, proteomic analysis was performed on fecal samples, targeting to investigate this ...[more]

PMID: 38975221

Similar Datasets

Project description:Background and Aims: Many inflammatory diseases are associated with microbial dysbiosis, which may considerably alter the production of short-chain fatty acids (SCFAs). SCFAs are produced in the large bowel through bacterial fermentation of dietary fiber and play an important role in maintaining gut homeostasis. SCFAs, particularly acetate and butyrate, show beneficial immunomodulatory effects contributing to the prevention of inflammatory and allergic reactions. Thus, reduced production of SCFAs may impact on the mucosal immune responses critical to fighting pathogens. This study aims to determine the influence of SCFAs on a murine model of colonic bacterial infection. Methods: In the present study, we used acetate- (HAMSA) or butyrate- (HAMSB) yielding diets to deliver high concentrations of individual SCFAs to the large bowel of mice infected with C. rodentium. We assessed the effects of these SCFAs on clinical burden and gut pathogenicity in correlation with changes in bacteria growth, fecal microbiota composition, function and changes in the immunological profile. Results: Here we show in vitro that acetate and butyrate directly inhibited growth of the attaching and effacing (A/E) pathogen C. rodentium in a bacteriostatic manner. This correlated with reduced expression of Tir, a gene responsible for bacterial adherence and pathogenicity. Interestingly, HAMSA-fed mice presented reduced clinical scores during C. rodentium infection associated with high concentrations of fecal acetate. This was linked with compositional and functional changes in the microbiota when examining 16s sequencing and proteomics analysis. The HAMSA mediated is protection involved increased expression IL-22 and Muc-2 in the colon and increased numbers of CD8αα+ TCRγδ T cells in the colonic epithelium. These effects were dependent on GPR43, a metabolite-sensing GPCR that binds acetate. Conclusions: We established a promising new approach to moderate bacterial gut infections by manipulating the gut microbiota and mucosal immune tolerance through diets that yield the SCFA acetate.